Analysis of B-ultrasound and contrast-enhanced ultrasound characteristics of different hepatic neuroendocrine neoplasm

Table 4 Comparison of contrast-enhanced ultrasound characteristics transferred from different sources of hepatic neuroendocrine neoplasm, n (%)

Contrast-enhanced ultrasound characteristics		Gastrointestinal tract, n = 20	Pancreas, n = 29	Other sites, n = 6	t/χ2	P value
Initial enhancement time in s		16.28 ± 5.82	16.83 ± 6.16	15.22 ± 4.92	1.305	0.372
Washout to iso-enhancement time in s		28.82 ± 12.38	27.29 ± 14.92	2 1.83 ± 11.23	0.924	0.477
Washout to hypo-enhancement time in s		64.93 ± 36.29	55.28 ± 31.83	58.21 ± 29.65	0.874	0.592
Enhancement level at arterial phase	High	19 (95.0)	28 (96.6)	6 (100.0)	0.335	0.846
	Equal	1 (5.0)	1 (3.4)	0 (0)
	Low	0 (0)	0 (0)	0 (0)
Enhancement level at portal venous phase	Equal	2 (10.0)	5 (17.2)	0 (0)	-	0.6101
	Low	18 (90.0)	24 (82.8)	6 (100.0)
Enhancement level at late phase	Equal	1(5.0)	1(3.4)	0 (0)	-	1.0001
	Low	19 (95.0)	28 (96.6)	6 (100.0)
Enhancement forms	Fast forward and fast out	19 (95.0)	28 (96.6)	6 (100.0)	-	1.0001
	Equal/slow forward and fast out	1 (5.0)	1 (3.4)	0 (0)
Enhancement forms	Uniform	13 (65.0)	16 (55.2)	4 (66.7)	-	0.7291
	Non-uniform	7 (35.0)	13 (44.8)	2 (33.3)
Tumor vasculature	Yes	14 (70.0)	17 (58.6)	3 (50.0)	-	0.6671
	No	6 (30.0)	12 (41.4)	3 (50.0)
Tumor necrosis	Yes	4 (20.0)	10 (34.5)	2 (33.3)	-	0.5691
	No	16 (80.0)	19 (65.5)	4 (66.7)
Capsule enhancement	Yes	2 (10.0)	4 (13.8)	1 (16.7)	-	1.0001
	No	18 (90.0)	25 (86.2)	5 (83.3)

¹Represent Fisher’s exact test.